MedTrace Logo

Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

NCT00183430 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-06-14

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals taking selective serotonin reuptake inhibitors.

Conditions

  • Post-Traumatic Stress Disorder
  • Sleep Initiation and Maintenance Disorders

Interventions

DRUG

Prazosin

Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.

DRUG

Placebo

Placebo capsules are taken orally twice per day at 10 am and bedtime.

BEHAVIORAL

Psychotherapy

All participants will undergo psychotherapy during medication treatment period.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Seattle Institute for Biomedical and Clinical Research

    lead OTHER

Principal Investigators

  • Murray A. Raskind, MD · University of Washington/Department of Veterans Affairs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2009-05-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00183430 on ClinicalTrials.gov